Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
申请人:——
公开号:US20040077605A1
公开(公告)日:2004-04-22
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
申请人:Salvati E. Mark
公开号:US20050119228A1
公开(公告)日:2005-06-02
Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
[EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
申请人:ABBOTT LAB
公开号:WO2010138578A1
公开(公告)日:2010-12-02
Described herein are compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein L1, R1, R2, R3, R4, R5, and m are defined in the description. Methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as IGF-IR are also disclosed.
Design and Synthesis of 2-Methyl-7-aminobenzoxazole as Auxiliary in the Palladium(II)-Catalyzed Arylation of a<i>beta</i>-Positioned C(<i>sp</i><sup>3</sup>)H Bond
A palladium(II)‐catalyzed direct arylation of methylene C(sp3)H bonds by 2‐methyl‐7‐aminobenzoxazole as an effective auxiliary is reported. This process exhibited high beta‐site selectivity, broad substrate scope, and compatibility with different functional groups with moderate to high yields up to 89%.
[EN] FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION<br/>[FR] COMPOSES DE SUCCINIMIDE HETEROCYCLIQUES LIES PAR FUSION ET SUBSTANCES ANALOGUES, MODULATEURS DE LA FONCTION DU RECEPTEUR HORMONAL NUCLEAIRE
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2003062241A1
公开(公告)日:2003-07-31
Fused cyclic compounds method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.